Patents
Literature
81 results about "Human liver" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The liver is a vital organ normally present in humans, in the upper right quadrant of the abdomen. The liver has a wide range of functions, including detoxification of various metabolites, protein synthesis, and the production of biochemicals necessary for digestion. The liver is necessary for survival, and there is currently no way to compensate for the absence of liver function in the long term, although liver dialysis techniques can be used in the short term. The liver is a gland and plays a major role in metabolism with numerous functions in the human body, including regulation of glycogen storage, decomposition of red blood cells, plasma protein synthesis, hormone production, and detoxification. The liver lies below the diaphragm in the abdominal-pelvic region of the abdomen. It produces bile, an alkaline compound which aids in digestion via the emulsification of lipids. The liver's highly specialized tissue consisting of mostly hepatocytes regulates a wide variety of high-volume biochemical reactions, including the synthesis and breakdown of small and complex molecules, many of which are necessary for normal vital functions.
Liver progenitor organ culture medium and culture method
The invention discloses a liver progenitor organoid culture medium and a culture method, and belongs to the technical field of organoid culture. The culture medium comprises a basic culture medium, Jagged-1, Dexamehysone, TGF (Transforming Growth Factor)-alpha, beta-mercaptoethanol, BMP4 (Bone Morphogenetic Protein 4), FGF2 (Fibroblast Growth Factor 2), specific addition factors Glutamax, HEPES (Hydroxyethyl PES), Nicotinamide, Penicillin and the like. The liver progenitor organoid is constructed by using the liver tissue for the first time, continuous growth and efficient proliferation of human liver progenitor cells in vitro can be promoted under the condition that gene editing is not carried out, meanwhile, the pluripotency of the liver progenitor organoid is maintained, and the consistency of specific marker expression is maintained; and a novel batch model is provided for the evaluation of hepatotoxicity at the present stage. From the long-term view, a foundation is laid for constructing a liver organ model with more advanced various differentiated cells.
Owner:CHENGDU AIMINGMAIDE MEDICAL LAB CO LTD
Apparatuses, systems, and methods for processing of three dimensional optical microscopy image data
Systems and methods for capturing and processing image data captured by an optical microscope, such as an Open Top Light Sheet (OTLS) microscope are disclosed. Image data can be processed by techniques including flat fielding, image depth correction, and edge correction, and pixel classification and image segmentation techniques can be applied to more accurately identify lipid droplets and fibrous structures for assessment of, for example, steatosis and fibrosis in human liver biopsy tissue samples. Systems and methods are also related to capturing low resolution images of a sample, identifying regions of interest, and then capturing high resolution image of the regions of interest to reduce memory used for storage, increase computation speed, and reduce computational power.
Owner:ALPENGLOW BIOSCIENCES INC
Tetrandrine ferulate and its application in preparing medicine for treating pulmonary fibrosis
The invention discloses a tetrandrine ferulate and its application in the preparation of a medicament for treating pulmonary fibrosis. The pharmacological effects of tetrandrine and ferulic acid, as well as those after salification, are studied. It is found that both have an anti-pulmonary fibrosis effect, and the two can be used in combination to synergistically exert a more excellent anti-pulmonary fibrosis efficacy. At the same time, the solubility of tetrandrine can also be increased. This has not been reported in existing literature. The tetrandrine ferulate of the present invention has lower cytotoxicity, and the cell viability of normal human liver cells LO-2 and human embryonic fibroblasts MRC-5 is higher than that of tetrandrine, which alleviates the burden of liver and lungs to a certain extent and has good safety.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Construction method and application of human acute liver injury and chemotaxis model based on normal liver organoids
The present application relates to a method for constructing a human acute liver injury and chemotaxis model based on a normal liver organoid and application thereof. Specifically, the present application provides a method for constructing a human liver organoid; further, contacting the liver organoid with a hepatotoxic drug can construct a human acute liver injury model; co-culturing the organoid or the injury model with immune cells can construct an in vitro immune cell chemotaxis model. The present application also provides reversible immunoaffinity magnetic beads for isolating VSIG4-positive macrophages and a method for isolating the same. The human liver organoid, acute liver injury model and chemotaxis model of the present application can be used for screening drugs for treating acute liver injury, evaluating the hepatotoxicity of compounds, researching the pathogenesis of acute liver injury and evaluating the effect of immunomodulatory drugs.
Owner:SHANGHAI TONGJI HOSPITAL
Compartmental analysis of extracorporeal liver perfusion systems
PCT designated stageWO2026055242A9Other blood circulation devicesControl devicesCholic acidLiver function
Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.
Owner:HEPQUANT LLC
A method, apparatus, system, and medium for predicting drug hepatotoxicity
The application provides a drug hepatotoxicity prediction method, device, system and medium, the method comprising: sequencing human liver cells after being contacted with a drug to be predicted to obtain a genome expression profile of the human liver cells after being contacted with the drug to be predicted; calculating the sum of the absolute values of the fold changes of the genes in the current gene pathway as the toxicity score of the current gene pathway according to the expression profile; calculating the Z value of the current gene pathway according to the toxicity score of the current gene pathway, the average value and the standard deviation value of the toxicity scores of the gene pathways calculated multiple times by a plurality of preset gene pathways; and predicting that the drug to be predicted has hepatotoxicity when the Z value is greater than 1.5. Therefore, the application can accurately, timely, effectively and sensitively predict drug hepatotoxicity without a large number of living animals as an experimental basis, and has good advantages in safety, environmental protection and animal protection. The application has the advantages of short experimental period and low cost.
Owner:CAPITALBIO CORP +2
AAVR knockout mouse in combination with human liver chimerism and methods of use and production of the same
PendingUS20260007122A1Compounds screening/testingCell receptors/surface-antigens/surface-determinantsImmune compromisedKnockout animal
The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.
Owner:AVACHROME INC
Preparation method and application of large-size human liver organoids
The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Liver-protecting wine and preparation method thereof
The invention discloses wine with a liver protection function and a preparation method thereof, and relates to the technical field of preparation of health-care wine. The wine comprises the following component raw materials: 20g of fructus lycii, 25g of dried chrysanthemum, 10g of radix puerariae, 10g of lucid ganoderma and 5g of radix angelicae sinensis, and the component raw materials are added into deuterium-depleted water to be subjected to heat preservation extraction at 85 DEG C and filtered to obtain extract liquid 1; extracting filter residues obtained by filtering in 68-72% vol of raw wine at normal temperature, and filtering to obtain extract liquor 2; and reducing the alcohol content of the filtrate 2 by using the filtrate 1 until the alcohol content is reduced to 45% vol, thereby obtaining the finished wine. Through verification, the obtained finished wine has a liver protection effect, can obviously reduce the damage of alcohol to the human liver, enriches wine products, and has an application prospect in the field of health-care wine.
Owner:SICHUAN YIBIN ZHUHAI WINERY +1
Devices and Methods to Improve and Assess Viability of Human Livers
The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.
Owner:THE GENERAL HOSPITAL CORP
Multi-zonal liver organoids
PCT designated stageWO2025212920A1HepatocytesGenetically modified cellsPluripotential stem cellDisease
Disclosed herein are improved pluripotent stem cell-derived multi-zonal liver organoids, having two or more hepatocyte subpopulations, and methods of producing the same, by coculturing a first human liver organoid (HLO) with a bilirubin-treated second HLO, and contacting the co-cultured HLOs with bilirubin for a period of time sufficient for the co-cultured HLOs to self-assemble and fuse into interconnected dual organoids. The first HLO can be an ascorbateenriched HLO, such as a functional L-gulonolactone oxidase (GULO)-expressing HLO. In particular embodiments, the hepatocyte subpopulations can include zone 1 and zone 3 hepatocyte subpopulations, or zone 1, zone 2, and zone 3 hepatocyte subpopulations. Also disclosed are methods of studying or treating a liver-related disease or disorder using the described multi-zonal liver organoids.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Application of an oxamide compound in the preparation of anti-liver cancer drugs
The present invention discloses an application of an oxamide compound in the preparation of an anti-liver cancer drug. The oxamide compound is N-(4,5,6,7-tetrahydro-1H-indazole-5-)-N'-(4-(p-tolyl)phenyl)oxamide, and the molecular formula is C 22 H 22 N4O3, with a molecular weight of 390.44 and a structural formula as shown in Formula (I), investigated the effect of N-(4,5,6,7-tetrahydro-1H-indazole-5-)-N'-(4-(p-tolyl)phenyl)oxalamide on the proliferation of liver cancer cells. The results showed that N-(4,5,6,7-tetrahydro-1H-indazole-5-)-N'-(4-(p-tolyl)phenyl)oxalamide exhibited significant anti-proliferation activity against human liver cancer cells (Hep G2, Hep 3B, PLC / PRF / 5, and Huh7), while exhibiting low toxicity against normal human liver cells (LX-2). This suggests that it possesses strong anti-liver cancer activity and excellent cell selectivity. Therefore, it is expected to be used in the preparation of anti-liver cancer drugs.
Owner:AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
Application of ginsenoside Rg1 in preparation of product for treating oxaliplatin-induced liver injury
The invention discloses application of ginsenoside Rg1 in preparation of a product for treating oxaliplatin-induced liver injury, and belongs to the technical field of medicines. Experimental verification shows that after ginsenoside Rg1 is administrated, the survival rate of HL-7702 human hepatocytes induced by oxaliplatin is increased, the content of transaminase indexes AST and ALT in the cells is obviously reduced, the content of active oxygen is obviously reduced, and the condition of mouse liver injury can be obviously improved. The experimental results show that the ginsenoside Rg1 can improve the liver injury induced by oxaliplatin, and a new technical thought is provided for preparing the product for treating the liver injury induced by oxaliplatin.
Owner:DALIAN NATIONALITIES UNIVERSITY
Extracellular matrix for three-dimensional cell culture and preparation method thereof
The invention relates to the field of cell culture, in particular to an epimatrix for three-dimensional cell culture and a preparation method of the epimatrix. The external matrix comprises xanthan gum, polyvinyl alcohol methyl acrylate, serum protein, arginine, trehalose, mannitol, dimethyl sulfoxide, ethylene glycol and a bacteriostatic agent. During preparation, dimethyl sulfoxide and ethylene glycol are mixed firstly, serum protein and an aqueous solution of xanthan gum are sequentially added to the surface layer of the mixture, oxygen is introduced from the bottom layer of the mixture, and a first precursor solution is obtained; introducing carbon dioxide into the bottom layer of a mixed aqueous solution of trehalose, mannitol and arginine to obtain a second precursor solution; after the first precursor solution and the second precursor solution are uniformly mixed, the polyvinyl alcohol methyl acrylate and the bacteriostatic agent are added and uniformly mixed again to obtain the epimatrix, and the epimatrix highly simulates the epimatrix in the human liver tissue and is beneficial to construction of cell spheres or complex tissue structures closer to the in-vivo physiological state.
Owner:SUZHOU UNIV
Vinegar guide as well as formula and preparation method thereof
The invention relates to a vinegar guide as well as a formula and a preparation method thereof. The invention relates to a vinegar guide, which is a formula vinegar beverage and seasoning which can be directly taken orally. The vinegar guide takes original vinegar as a base material, and components are selected from substances which are allowed to be used according to a traditional food and traditional Chinese medicinal material catalog published by the country. Adding drinking water according to a ratio, performing high-temperature (sterilization) to stimulate the properties of medicinal and edible substances, performing low-temperature decoction to overflow effective components, and performing seasoning. The requirements of related laws and technical specifications such as Food Safety Law of the People's Republic of China are met. According to the theory of'guiding medicine to channel 'of Chinese traditional medicine and pharmacy, medicinal and edible Chinese herbal medicines are soaked in vinegar and decocted with water, so that material attribute components can be effectively stimulated to directly act on human liver and stomach visceral meridians, and the requirement of human organs on absorption of the medicinal and edible material attribute components is met. And meanwhile, the health-care wine can effectively eliminate or relieve discomfort of a human body caused by drinking.
Owner:魏铁汉
Construction method of 3D printing liver organoid scaffold of FH1-loaded sodium alginate microsphere assembled mesenchymal stem cells
ActiveCN120924476AHepatocytesSkeletal/connective tissue cellsMesenchymal stem cellBiomedical engineering
The invention discloses a construction method of a 3D printing liver organoid scaffold of FH1-loaded sodium alginate microsphere assembled mesenchymal stem cells. The construction method comprises the following steps: preparing CaO2 (at) ZIF-8 (at) SL; preparing sodium alginate microspheres FH1 (at) SA carrying FH1; and preparing the 3D printing liver organ stent. The 3D printing liver organ-like scaffold prepared by the method can significantly enhance the differentiation of human umbilical cord mesenchymal stem cells to functional stem cells, and can be used for constructing a human liver organ-like model.
Owner:NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
Liver portal vein system thrombus identification method and device
ActiveCN120823632ASubcutaneous biometric featuresBlood vessel patternsPortal venous systemImaging processing
The invention discloses a hepatic portal vein system thrombus identification method and device, and relates to the technical field of medical image processing, and the method comprises the steps: inputting a to-be-processed CTA image into a rough segmentation model, and outputting a blood vessel cavity; the vascular cavity comprises a blood vessel and thrombus in the blood vessel; the rough segmentation model is obtained by training an nnunet network; carrying out statistics on HU value distribution of the pixels in the blood vessel cavity, and determining a segmentation threshold value for segmenting thrombus in combination with a human liver tissue standard HU value; based on a density clustering algorithm, determining a clustering center coordinate of the thrombus in the blood vessel; taking the clustering center coordinate as a seed point, carrying out region growth according to the similarity between a pixel HU value in a blood vessel cavity and the segmentation threshold value until a blood vessel boundary is encountered or no to-be-grown pixel point exists, and obtaining a fine segmentation result; the fine segmentation result comprises each pixel where the thrombus is located. The thrombus recognition accuracy of the hepatic portal vein system can be improved.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY +1
Human liver chimeric non-human animal with deficient p450 oxidoreductase and methods of using same
InactiveUS20250268240A1Compounds screening/testingNucleic acid vectorLiver functionsP450 oxidoreductase
The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.
Owner:BAYLOR COLLEGE OF MEDICINE
A method for constructing a 3D-printed liver organoid scaffold loaded with fh1 alginate sodium microspheres assembled mesenchymal stem cells
The application discloses a construction method of a 3D printing liver organoid support loaded with mesenchymal stem cells assembled by FH1 sodium alginate microspheres, and comprises the following steps: preparing CaO2@ZIF-8@SL; preparing FH1-loaded sodium alginate microspheres FH1@SA; and preparing a 3D printing liver organoid support. The 3D printing liver organoid support prepared by the method can significantly enhance the differentiation of human umbilical cord mesenchymal stem cells into functional stem cells, and can be used for constructing a human liver organoid model.
Owner:NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
NON-HUMAN CHIMERATIVE ANIMAL WITH HUMAN LIVER DEFICIENCED IN P450 OXIDOREDUCTASE AND METHOD FOR USE THEREMISH
Owner:BAYLOR COLLEGE OF MEDICINE
Human liver vessel blood flow simulation method based on deep learning
The invention relates to the technical field of blood flow simulation, in particular to a human liver blood vessel blood flow simulation method based on deep learning, and the method comprises the steps: reconstructing an original liver blood vessel medical image to obtain a water tightness STL model of a liver blood vessel; then an open source solver OpenFOAM is used for conducting analysis domain division on the model, and information of a blood flow velocity field and a pressure field is obtained through solving; performing data preprocessing, performing time sequence processing on the data to obtain a data form suitable for the PBTCNN, and inputting the data into the PBTCNN for training; and finally, storing the trained model for predicting a pressure field and a velocity field. The PBTCNN realizes partial replacement of a traditional CFD method for hemodynamic analysis, can reduce the cost of blood flow simulation, does not need to reduce the calculation cost based on the characteristics of grid division, and can obtain a blood flow simulation result more quickly while guaranteeing the precision.
Owner:QINGDAO EMIBOCHUANG MEDICAL TECH CO LTD
Monoclonal antibodies recognizing human liver progenitor cells and hybridoma cell line HLPC1
The present invention discloses a monoclonal antibody for recognizing human liver progenitor cells and a hybridoma cell line HLPC1. Human liver progenitor cells are used as antigens and a hybridoma cell line HLPC1 is constructed by using monoclonal antibody technology, and the deposit number is CCTCC NO: C202253. The hybridoma cell line HLPC1 secretes a monoclonal antibody for recognizing human liver progenitor cells. Flow cytometry, immunohistochemistry, immunofluorescence and immunoblotting are established with this monoclonal antibody as a probe for detecting and analyzing human liver progenitor cells. The present invention provides a specific method for the study of human liver progenitor cells, and various detection techniques based on monoclonal antibodies of human liver progenitor cells can also be used in the study of human liver damage and regeneration.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Food nourishing composition, food nourishing liquid and eating method
PendingCN120549224ANatural extract food ingredientsFood ingredient functionsBiotechnologyHealthy diet
The invention provides a food nourishing composition, food nourishing liquid and an eating method, and belongs to the technical field of healthy diet. The food nourishing composition comprises the following raw materials in parts by weight: 11-13 parts of red beans, 10-12 parts of coix seeds, 10-12 parts of black beans, 10-12 parts of black rice, 10-12 parts of white hyacinth beans, 10-12 parts of red beans, 10-12 parts of peas, 10-12 parts of broad beans and 10-12 parts of chickpeas. According to the food-nourishing composition, the raw materials are the whole grains, through reasonable matching of the raw materials, nutrients such as carbohydrates, protein, vitamins, mineral substances and dietary fibers needed by the body can be effectively supplemented, the body nutrition can be balanced, the sub-health state of the body can be improved, and the immunity and the self-healing capacity can be improved. In addition, all the raw materials of the food-nourishing composition are grains, so that the food-nourishing composition has no toxic or side effect, does not cause any harm to viscera such as liver and kidney of a human body, and is suitable for most people to eat.
Owner:SHANDONG YUDIKANG HEALTH MANAGEMENT CO LTD
Human liver scaffold
The present invention relates to a method for decellularizing human liver tissue to produce a human liver extracellular matrix (ECM) scaffold, for example, for use in therapy or disease modeling. The method involves, for example, freezing and thawing, followed by subjecting the liver tissue to multiple cycles of osmotic stress to mechanically disrupt cells in the tissue, detergent treatment, and protease and / or DNase treatment to produce a decellularized human ECM scaffold.
Owner:UCL BUSINESS LTD
Humanized Anti-claudin-1 antibodies and uses thereof
The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy. Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
A method for rapid determination of tigecycline and GD-MET-1 in human liver microsomal incubation system by LC-MS / MS
This invention belongs to the field of drug metabolism and analytical chemistry, specifically relating to a method for the rapid determination of tigustastat and its active metabolite GD-MET-1 concentrations in a human liver microsome incubation system using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The method first prepares stock solutions of tigustastat, GD-MET-1, and an internal standard, and prepares a series of standard curve solutions, quality control solutions, and precipitant solutions containing the internal standard. Next, the sample with the added precipitant solution undergoes vortexing and centrifugation pretreatment. Finally, chromatographic and mass spectrometric conditions are set, and the analysis is performed by LC-MS / MS. This method has been validated for specificity, accuracy, precision, matrix effects, recovery, residues, and stability, and can be reliably used for metabolic stability studies of tigustastat and GD-MET-1 in a human liver microsome incubation system, GD-MET-1 formation studies, metabolic enzyme identification, enzyme kinetic studies, and drug interaction studies.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Manufacturing method for prolonging in-vivo half-life period of artificial exosome
The invention discloses a preparation method for prolonging the in-vivo half-life period of an artificial exosome. The preparation method comprises the following steps: S1, extracting the exosome; s1.1, cell culture: culturing the human liver Kupffer cells for 7 days; s1.2, primary centrifugation: collecting a culture solution, and centrifuging to remove cells and large fragments; s1.3, secondary clarification: transferring the supernatant to a new tube, and centrifuging to further remove smaller cell debris; s1.4, ultracentrifugal precipitation of the exosome: transferring the supernate again, and centrifugally precipitating the exosome; s1.5, re-suspending the exosome: gently re-suspending the precipitate with PBS, and carrying out ultracentrifugation to remove impurities; s2, platelet membrane component extraction; s3, combining the exosome with the platelet membrane component. According to the invention, the in-vivo half-life period of the exosome is greatly prolonged by using a simpler process and cost, and the half-life period can reach 24-48 hours.
Owner:苏州铂法生物科技有限公司
Tri-fused ring compound and application thereof
The invention discloses a tricyclic compound and application thereof, and belongs to the technical field of medicine synthesis. The invention provides a tricyclic compound as shown in a formula I. The tricyclic compound can be used for broad-spectrum virus resistance, can effectively inhibit the activity of SARS-CoV, MERS-CoV, SARS-CoV-2 and other coronaviruses and block the replication of the viruses in the body of a patient, and particularly has more advantages in the aspects of pharmacokinetic property, human CYP inhibition rate, cytotoxicity, human liver microsome stability and the like. The compound disclosed by the invention can be used as a generic coronavirus resisting drug, and particularly provides a new choice for developing a drug for preventing and treating diseases related to novel coronavirus infection. Formula I
Owner:SICHUAN UNIV
A dimer compound with endothelin A (ETA) receptor antagonist activity and its application
This invention belongs to the field of medicinal chemistry, specifically relating to a dimeric compound with endothelin A (ETA) receptor antagonist activity and its applications. The compound of this invention is rapidly metabolized to atrasentan in human liver microsomes. In rats, after oral administration, it exhibits excellent absorption, high bioavailability, and a long half-life, significantly lowering blood pressure and improving kidney injury. Furthermore, its weak binding to P-GP and its non-substrate nature further enhance its bioavailability. The compound of this invention, or its pharmaceutically acceptable salt, holds promise for use in the preparation of drugs for the treatment and prevention of ETA receptor antagonist-related diseases, such as chronic kidney disease and hypertension.
Owner:JIANG SU PHARMAMAXCORP
Human liver metastasis-derived colon cancer cell line crc-x1 and use thereof
PendingCN122104594AMicrobiological testing/measurementArtificial cell constructsOncologyCancer research
The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY